Barinthus Biotherapeutics Appoints Douglas Swirsky as Chief Financial Officer
TAKEN PRIVATEApr 22, 2026
Position
Chief Financial Officer
Company
Barinthus Biotherapeutics plc
Douglas Swirsky
OxfordBiotechnologyTherapeuticsBiopharma
Description
Douglas Swirsky has been appointed as Chief Financial Officer and principal accounting officer of Barinthus Biotherapeutics, effective May 1, 2026. He brings over 25 years of experience in financial leadership roles, including his most recent position as CFO of MaxCyte.
Who to call at Barinthus Biotherapeutics plc, and when
A new leader at Barinthus Biotherapeutics plc brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Barinthus Biotherapeutics plc raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Barinthus Biotherapeutics plc, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Barinthus Biotherapeutics plc
Location
Oxford, England, United Kingdom
About
Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. With a broad pipeline, built around three proprietary platform technologies: ChAdOx, MVA and SNAP; Barinthus Bio is advancing a pipeline of four product candidates across a diverse range of therapeutic areas.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Barinthus Biotherapeutics plc changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
OxfordBiotechnologyTherapeuticsBiopharma